Drug-Resistant Staph (VISA)

Clear→ stable

Invasive bacterial

Current NYS Status

4 cases in 2024 (baseline: ~11). Low absolute count.

2024 statewide cases: 4

Source: NYSDOH Annual Communicable Disease Report 2024 + 5-yr baseline

What is it?

Vancomycin-Intermediate Staphylococcus aureus (VISA) is a form of Staphylococcus aureus with reduced susceptibility to vancomycin, the antibiotic of last resort for MRSA. NYS had 4 cases in 2024 (excluding NYC). VISA represents a critical stage in the evolution of antibiotic resistance — full resistance (VRSA) would render common staph infections essentially untreatable.

How it spreads

Spreads through contact with infected wounds or colonized body sites, and via healthcare worker hands or contaminated equipment. Healthcare settings are the primary transmission environment.

Symptoms

Similar to other Staph aureus infections: wound infections, bloodstream infections (sepsis), pneumonia, endocarditis, and abscesses. The key clinical concern is failure to respond to standard vancomycin treatment.

Who is at risk?

Patients with prolonged healthcare exposure, multiple recent antibiotic courses (especially vancomycin), dialysis patients, patients with indwelling catheters, and those with prior MRSA infections.

What you can do

🛡Healthcare facilities must implement rigorous contact precautions and hand hygiene for VISA patients

🛡Antimicrobial stewardship — using antibiotics only when necessary — is essential to slow resistance development

⚕️Infectious disease specialist consultation is essential; newer agents (daptomycin, ceftaroline, linezolid combinations) may be effective

Tier B — Annual report tracking

Based on NYSDOH annual communicable disease report. Threat level reflects 2024 case counts compared to the 5-year baseline.

Seasonality: year round

This information is for general public health awareness and is not a substitute for professional medical advice, diagnosis, or treatment.